MentionFox
Home › Executive changes › Curanex Pharmaceuticals Inc
Leadership changes · CURX · SEC Form 8-K, Item 5.02

Leadership changes at Curanex Pharmaceuticals Inc (2026)

Before you join, sell to or invest in Curanex Pharmaceuticals Inc

MentionFox check on Curanex Pharmaceuticals Inc: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/curanex-pharmaceuticals

Check Curanex Pharmaceuticals Inc before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Curanex Pharmaceuticals Inc?

Who joined and who left Curanex Pharmaceuticals Inc (CURX)? 1 appointment and 1 departure reported from 2026-01-05 to 2026-03-06, each cited to the company's own filing.

Wanjun Zhang was named Chief Financial Officer of Curanex Pharmaceuticals Inc, succeeding Haiyan Yang, effective January 1, 2026. As of November 14, 2026, Curanex Pharmaceuticals Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 5, 2026 to March 6, 2026, naming 1 appointment and 1 departure (Form 8-K, January 5, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Sell to companies like Curanex Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes3
In (appointed)1
Out (departing)1
Latest filing2026-03-06

Curanex Pharmaceuticals Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-05 to 2026-03-06. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Curanex Pharmaceuticals Inc files it.

Also on the record for Curanex Pharmaceuticals Inc

DateRecordFigureOur pageSource
August 26, 2025IPO filing, Form 424B4$4 a shareIPO filingsSource
August 26, 2025IPO filing, Form 424B4$4 a shareIPO filingsSource
July 18, 2025IPO filing, Form S-1/A$4 to $6 a shareIPO filingsSource
July 1, 2025IPO filing, Form S-1/A$4 to $6 a shareIPO filingsSource
March 17, 2025IPO filing, Form S-1/A$4 to $6 a shareIPO filingsSource
February 14, 2025IPO filing, Form S-1/A$4 to $6 a shareIPO filingsSource
November 27, 2024IPO filing, Form S-1/A$4 to $6 a shareIPO filingsSource
November 1, 2024IPO filing, Form S-1/A$4 to $6 a shareIPO filingsSource
October 16, 2024IPO filing, Form S-1$4 to $6 a shareIPO filingsSource

Selling to them or working with them? See who runs Curanex Pharmaceuticals Inc now and the warning signs.

Free to see. No signup.

Want the whole picture on Curanex Pharmaceuticals Inc?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on Curanex Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Curanex Pharmaceuticals Inc covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    11 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-06Reportednot named in the filing8-K, 2026-03-06
2026-01-05OutChief Financial Officer8-K, 2026-01-05
2026-01-05InChief Financial Officer2026-01-018-K, 2026-01-05

Why did they leave? What the filings say

For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.

Who leads Curanex Pharmaceuticals Inc, as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Curanex Pharmaceuticals Inc?

New leaders reset buying decisions — get the Full Report on Curanex Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Curanex Pharmaceuticals Inc

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Financial Officer at Curanex Pharmaceuticals Inc, with the record behind each one.

Find candidates like Chief Financial Officer at Curanex Pharmaceuticals Inc

Every change, in the filing's words

Filed 2026-03-06 · 8-K

Reported

The CEO Agreement relates to the continuation of Mr. Liu's services as Chief Executive Officer and President of the Company since his appointment to these positions in February 2024, and requires Mr. Liu to provide the services and responsibilities consistent with the position of chief executive officer and president of a publicly listed company, including taking overall responsibility for the Company's management, corporate strategy, research and development oversight, clinical and regulatory coordination, capital markets activities, and execution of the Company's business, subject at all tim

Also stated in this filing

  • CEO Employment Agreement On March 2, 2026, Curanex Pharmaceuticals Inc (the "Company") entered into an executive employment agreement with Mr. Jun Liu, the Chief Executive Officer and President of the Company, effective March 1, 2026 (the "CEO Agreement").
  • The term of the CEO Agreement begins on the Effective Date and ends on the fourth anniversary of the Effective Date, until terminated earlier by the parties under the terms of the CEO Agreement.
  • It may be renewed upon the same terms and conditions for successive one-year periods, upon mutual consent of the parties.
  • If the CEO Agreement is terminated due to Mr. Liu's death, his beneficiary shall receive any salary, benefits and reimbursements that would otherwise have been payable to Mr. Liu as of the date of his death.
  • If the CEO Agreement is terminated due to Mr. Liu's disability, upon determination that a disability exists, after consultation with a qualified, independent physician, Mr. Liu shall be entitled to receive any amounts of salary earned, accrued and owing but not yet paid and any benefits accrued and due under any applicable benefit plans and programs of the Company.
Filed 2026-01-05 · 8-K

Departing: Haiyan Yang, Chief Financial Officer

On December 31, 2025, Haiyan Yang informed Curanex Pharmaceuticals Inc, a Nevada corporation (the "Company") of her resignation as Chief Financial Officer and Treasurer of the Company, effective immediately.

Appointed: Wanjun Zhang, Chief Financial Officer, effective 2026-01-01

On December 31, 2025, in connection with the resignation of Ms. Yang, the Company appointed Wanjun Zhang as Chief Financial Officer and Treasurer of the Company, effective January 1, 2026.

Also stated in this filing

  • Mr. Zhang, 52, has over 20 years of financial and accounting related experience, specializing in financial reporting, compliance, and business strategy.
  • Before joining Curanex, from July 2020, he provided financial consulting and accounting services to small and medium size companies, focusing on financial reporting, compliance and business strategy.
  • In connection with Mr. Zhang's appointment, on December 31, 2025, the Company entered with him into a consulting agreement (the "CFO Agreement"), for the initial term of two (2) years from January 1, 2026 (the "Effective Date").

Tools for this story

Each opens in a new tab, filled in for Curanex Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/curanex-pharmaceuticals
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Curanex Pharmaceuticals Inc executive departure 2026. MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/curanex-pharmaceuticals